JP2015535174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535174A5 JP2015535174A5 JP2015531340A JP2015531340A JP2015535174A5 JP 2015535174 A5 JP2015535174 A5 JP 2015535174A5 JP 2015531340 A JP2015531340 A JP 2015531340A JP 2015531340 A JP2015531340 A JP 2015531340A JP 2015535174 A5 JP2015535174 A5 JP 2015535174A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- pharmaceutically acceptable
- acceptable salt
- molecules
- ribonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 29
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 125000002652 ribonucleotide group Chemical group 0.000 claims 14
- 239000002773 nucleotide Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 108091081021 Sense strand Proteins 0.000 claims 9
- 230000000692 anti-sense effect Effects 0.000 claims 8
- 108091028664 Ribonucleotide Proteins 0.000 claims 7
- 239000002336 ribonucleotide Substances 0.000 claims 7
- HYCSHFLKPSMPGO-UHFFFAOYSA-N 3-hydroxypropyl dihydrogen phosphate Chemical group OCCCOP(O)(O)=O HYCSHFLKPSMPGO-UHFFFAOYSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 208000016354 hearing loss disease Diseases 0.000 claims 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 3
- RXQZLSRIOOYKLF-UHFFFAOYSA-N 5H-pyrazolo[4,3-d]triazine Chemical compound N1=NN=C2C=NNC2=C1 RXQZLSRIOOYKLF-UHFFFAOYSA-N 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 108091046915 Threose nucleic acid Proteins 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 238000010322 bone marrow transplantation Methods 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims 1
- -1 5,6,7,8-tetrahydro-2-naphthalenebutyric acid phosphodiester Chemical class 0.000 claims 1
- 208000035657 Abasia Diseases 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000012639 Balance disease Diseases 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical group O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 239000003814 drug Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000028329 epileptic seizure Diseases 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 108700025694 p53 Genes Proteins 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699884P | 2012-09-12 | 2012-09-12 | |
| US61/699,884 | 2012-09-12 | ||
| PCT/US2013/059349 WO2014043292A1 (en) | 2012-09-12 | 2013-09-12 | Double-stranded oligonucleotide molecules to p53 and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535174A JP2015535174A (ja) | 2015-12-10 |
| JP2015535174A5 true JP2015535174A5 (enExample) | 2016-11-04 |
| JP6364009B2 JP6364009B2 (ja) | 2018-07-25 |
Family
ID=49304313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531340A Expired - Fee Related JP6364009B2 (ja) | 2012-09-12 | 2013-09-12 | Ｐ５３に対する二本鎖オリゴヌクレオチド分子、およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9932578B2 (enExample) |
| EP (1) | EP2895607B1 (enExample) |
| JP (1) | JP6364009B2 (enExample) |
| CN (1) | CN104619844A (enExample) |
| BR (1) | BR112015004747A2 (enExample) |
| CA (1) | CA2880290C (enExample) |
| DK (1) | DK2895607T3 (enExample) |
| ES (1) | ES2872349T3 (enExample) |
| HK (1) | HK1210216A1 (enExample) |
| WO (1) | WO2014043289A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2880290C (en) | 2012-09-12 | 2020-10-27 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof |
| EP3019559A4 (en) | 2013-08-22 | 2017-04-05 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| KR102676814B1 (ko) | 2015-02-26 | 2024-06-21 | 소니그룹주식회사 | 접합 그룹을 포함하는 수용성 형광 또는 착색 염료 |
| WO2016138457A1 (en) | 2015-02-26 | 2016-09-01 | Sony Corporation | Phenylethynylnaphthalene dyes and methods for their use |
| JP6849599B2 (ja) | 2015-05-11 | 2021-03-24 | ソニー株式会社 | 超明色ダイマーまたはポリマー染料 |
| KR102530707B1 (ko) | 2016-04-01 | 2023-05-11 | 소니그룹주식회사 | 초휘도 이량체성 또는 중합체성 염료 |
| US11434377B2 (en) | 2016-04-01 | 2022-09-06 | Sony Corporation | Ultra bright dimeric or polymeric dyes with rigid spacing groups |
| KR20180133890A (ko) | 2016-04-06 | 2018-12-17 | 소니 주식회사 | 스페이싱 링커 그룹을 포함하는 초고명도 이량체성 또는 중합체성 염료 |
| WO2017197014A2 (en) | 2016-05-10 | 2017-11-16 | Sony Corporation | Compositions comprising a polymeric dye and a cyclodextrin and uses thereof |
| WO2017196954A1 (en) | 2016-05-10 | 2017-11-16 | Sony Corporation | Ultra bright polymeric dyes with peptide backbones |
| EP3455300A1 (en) | 2016-05-11 | 2019-03-20 | Sony Corporation | Ultra bright dimeric or polymeric dyes |
| JP7068191B2 (ja) | 2016-06-06 | 2022-05-16 | ソニーグループ株式会社 | 蛍光または有色レポーター基を含むイオン性ポリマー |
| US12018159B2 (en) | 2016-07-29 | 2024-06-25 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes and methods for preparation of the same |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| JP7551056B2 (ja) | 2017-10-05 | 2024-09-17 | ソニーグループ株式会社 | プログラマブルなポリマー薬物 |
| EP3691689A1 (en) | 2017-10-05 | 2020-08-12 | Sony Corporation | Programmable dendritic drugs |
| CN111836645A (zh) | 2017-11-16 | 2020-10-27 | 索尼公司 | 可编程的聚合药物 |
| EP4616912A3 (en) | 2018-01-12 | 2025-11-19 | Sony Group Corporation | Phosphoalkyl ribose polymers comprising biologically active compounds |
| WO2019140301A1 (en) | 2018-01-12 | 2019-07-18 | Sony Corporation | Polymers with rigid spacing groups comprising biologically active compounds |
| KR102742386B1 (ko) | 2018-03-19 | 2024-12-16 | 소니그룹주식회사 | 형광 신호 향상을 위한 2가 금속의 사용 |
| WO2019182766A1 (en) | 2018-03-21 | 2019-09-26 | Sony Corporation | Polymeric tandem dyes with linker groups |
| KR102854332B1 (ko) | 2018-06-27 | 2025-09-03 | 소니그룹주식회사 | 디옥시리보오스를 포함하는 링커 군을 갖는 중합체성 염료 |
| KR102486779B1 (ko) | 2019-09-26 | 2023-01-12 | 소니그룹주식회사 | 링커 그룹을 갖는 중합체성 탠덤 염료 |
| CN110974804B (zh) * | 2019-11-13 | 2021-09-24 | 杭州师范大学 | p53信使RNA纳米粒及其制备方法和在制备治疗肿瘤药物中的应用 |
| EP4256078A1 (en) | 2020-12-07 | 2023-10-11 | Sony Group Corporation | Spacing linker group design for brightness enhancement in dimeric or polymeric dyes |
| WO2024023254A1 (en) * | 2022-07-27 | 2024-02-01 | E-Therapeutics Plc | Nucleic acid compounds |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| DK1695979T3 (da) | 1991-12-24 | 2011-10-10 | Isis Pharmaceuticals Inc | Gappede modificerede oligonukleotider |
| AU687736B2 (en) | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| DE69433036T2 (de) | 1993-09-03 | 2004-05-27 | Isis Pharmaceuticals, Inc., Carlsbad | Aminoderivatisierte nukleoside und oligonukleoside |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6235310B1 (en) | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| WO1999009046A1 (en) | 1997-08-21 | 1999-02-25 | Quark Biotech, Inc. | Hypoxia-regulated genes |
| EP1038016A2 (en) | 1997-12-16 | 2000-09-27 | Valentis Inc. | Needle-free injection of formulated nucleic acid molecules |
| EP2138191A1 (en) | 1998-01-05 | 2009-12-30 | University Of Washington | Enhanced transport using membrane disruptive agents |
| EP1096921B1 (en) | 1998-07-20 | 2003-04-16 | Protiva Biotherapeutics Inc. | Liposomal encapsulated nucleic acid-complexes |
| JP4777515B2 (ja) * | 1998-10-26 | 2011-09-21 | エイブイアイ バイオファーマ， インコーポレイテッド | ｐ５３モルホリノに基づくアンチセンス |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| AU2001281730A1 (en) | 2000-07-26 | 2002-02-05 | Chemometec A/S | Spatially resolved enzyme-linked assay |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| AU2003278112A1 (en) | 2002-10-18 | 2004-05-04 | Silence Therapeutics Ag | Factor involved in metastasis and uses thereof |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US20050136437A1 (en) | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| KR100939274B1 (ko) | 2004-08-16 | 2010-01-29 | 쿠아크 파마수티칼스 인코퍼레이티드 | 알티피801 억제제의 치료적 용도 |
| NL2000439C2 (nl) * | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutische toepassingen van inhibitoren van RTP801. |
| US8362229B2 (en) | 2006-02-08 | 2013-01-29 | Quark Pharmaceuticals, Inc. | Tandem siRNAS |
| WO2008008476A2 (en) | 2006-07-12 | 2008-01-17 | The Regents Of The University Of California | Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups |
| EP2137205A2 (en) | 2007-02-26 | 2009-12-30 | Quark Pharmaceuticals, Inc. | Inhibitors of rtp801 and their use in disease treatment |
| US20100292301A1 (en) | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
| CA2701845A1 (en) | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| WO2009116037A2 (en) | 2008-03-20 | 2009-09-24 | Quark Pharmaceuticals, Inc. | NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801 |
| US8431692B2 (en) | 2008-06-06 | 2013-04-30 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| EP2346883B1 (en) | 2008-09-23 | 2016-03-23 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| NZ591391A (en) | 2008-10-22 | 2012-10-26 | Quark Pharmaceuticals Inc | Non-invasive methods for treating eye disorders using a topical oligonucleotide composition |
| US20110288155A1 (en) * | 2008-12-18 | 2011-11-24 | Elena Feinstein | Sirna compounds and methods of use thereof |
| US8637482B2 (en) | 2009-06-08 | 2014-01-28 | Quark Pharmaceuticals, Inc. | Methods for treating chronic kidney disease |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| EP2649181B1 (en) | 2010-12-06 | 2016-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| CA2880290C (en) | 2012-09-12 | 2020-10-27 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof |
-
2013
- 2013-09-12 CA CA2880290A patent/CA2880290C/en not_active Expired - Fee Related
- 2013-09-12 ES ES13773450T patent/ES2872349T3/es active Active
- 2013-09-12 WO PCT/US2013/059341 patent/WO2014043289A2/en not_active Ceased
- 2013-09-12 DK DK13773450.5T patent/DK2895607T3/da active
- 2013-09-12 JP JP2015531340A patent/JP6364009B2/ja not_active Expired - Fee Related
- 2013-09-12 US US14/421,845 patent/US9932578B2/en not_active Expired - Fee Related
- 2013-09-12 HK HK15110939.6A patent/HK1210216A1/xx unknown
- 2013-09-12 EP EP13773450.5A patent/EP2895607B1/en active Active
- 2013-09-12 CN CN201380047225.6A patent/CN104619844A/zh active Pending
- 2013-09-12 US US14/426,513 patent/US9611474B2/en not_active Expired - Fee Related
- 2013-09-12 BR BR112015004747A patent/BR112015004747A2/pt not_active IP Right Cessation
-
2017
- 2017-02-15 US US15/433,400 patent/US10421962B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535174A5 (enExample) | ||
| JP7129702B2 (ja) | オーバーハングを有する二本鎖核酸複合体 | |
| JP6768664B2 (ja) | 分子の細胞内送達のためのペプチドおよびナノ粒子 | |
| EP3227445B1 (en) | Cell penetrating molecule | |
| JP2011522036A5 (enExample) | ||
| JP2019504112A5 (enExample) | ||
| JP2018513682A5 (enExample) | ||
| JP2017505623A5 (enExample) | ||
| JP2017532038A5 (enExample) | ||
| TWI723363B (zh) | 用於治療癌症之包含引導rna及內切酶的藥學組成物 | |
| UA118014C2 (uk) | Спосіб модифікації днк-мішені | |
| WO2006096754A3 (en) | Stabilized aptamers to psma and their use as prostate cancer therapeutics | |
| JP2013121977A5 (enExample) | ||
| JP2019503394A5 (enExample) | ||
| JP7333079B2 (ja) | 毒性が軽減した核酸 | |
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| JP2019526624A (ja) | 細胞透過性が向上したペプチド核酸複合体およびそれを含む薬学的組成物 | |
| JP5559159B2 (ja) | 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害 | |
| JP2016056136A (ja) | 血管内皮細胞増殖因子結合性核酸アプタマー及びその利用 | |
| JP2019506862A5 (enExample) | ||
| JP2013537404A5 (enExample) | ||
| de Franciscis | Challenging cancer targets for aptamer delivery | |
| Bartas et al. | Bioinformatics analyses and in vitro evidence for five and six stacked G-quadruplex forming sequences | |
| CA3109740A1 (en) | Blood-brain barrier permeable aptamer and application thereof | |
| US20170014521A1 (en) | Pharmaceutical compositions for high-capacity targeted delivery |